10-Hydroxycamptothecin

SKU: orb1225777

Description

(S)-10-Hydroxycamptothecin is a clinical therapy agent against hepatoma. (In Vitro):(S)-10-Hydroxycamptothecin (5-20 μg/L; 6 days; Hep G2 cells) treatment results in the cell cycle arrest at G2/M phase.(S)-10-Hydroxycamptothecin induces differentiation, down-regulates nuclear antigen (PCNA) and up-regulates wild-type protein p53 in Hep G2 cells.(S)-10-Hydroxycamptothecin inhibits L1210 leukemia cells with an IC50 of 1.15 μM.(In Vivo):(S)-10-Hydroxycamptothecin (10-Hydroxycamptothecin) against L1210 leukemia in mice is tested. At the optimal dose (15 mg/kg), (S)-10-Hydroxycamptothecin has a 71% increase in life span (ILS).

Key Properties

• CAS Number: 19685-09-7
• MW: 364.36
• Purity: >98% (HPLC)
• Formula: C₂₀H₁₆N₂O₅
• SMILES: O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=CC(O)=CC=C5N=C4C3=C2)=O
• Target: Topoisomerase
• Solubility: DMSO: 8 mg/mL warmed (21.95 mM)

Bioactivity

• In Vivo:
  (S)-10-Hydroxycamptothecin (10-Hydroxycamptothecin) against L1210 leukemia in mice is tested. At the optimal dose (15 mg/kg), (S)-10-Hydroxycamptothecin has a 71% increase in life span (ILS).
  Read more...
• In Vitro:
  (S)-10-Hydroxycamptothecin (5-20 μg/L; 6 days; Hep G2 cells) treatment results in the cell cycle arrest at G2/M phase. (S)-10-Hydroxycamptothecin induces differentiation, down-regulates nuclear antigen (PCNA) and up-regulates wild-type protein p53 in Hep G2 cells. (S)-10-Hydroxycamptothecin inhibits L1210 leukemia cells with an IC50 of 1.15 μM. Cell Cycle Analysis Cell line: Hep G2 cells. Concentration: 5 μg/L, 10 μg/L, 20 μg/L. Incubation time: 6 days. Result: Hep G2 cells were mainly arrested at G2/M phase.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ChEMBL 273862 | NSC 107124

Quick Database Links

Gene Symbol

Topoisomerase